Preeclampsia Clinical Trial
Official title:
Use of Combination Metformin and Esomeprazole in Preterm Pre-eclampsia: a Randomized Controlled Trial
Verified date | April 2024 |
Source | Christiana Care Health Services |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to better understand diagnosis and treatment of preterm preeclampsia. Currently, there are limited laboratory tests that can be used to diagnosis preeclampsia. Additionally, there are few treatments for this condition. This clinical trial will explore treatment options, Metformin and Esomeprazole, as well as serum markers that could improve the diagnosis and treatment of preterm preeclampsia.
Status | Active, not recruiting |
Enrollment | 4 |
Est. completion date | June 2025 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Women 18 years or older - Women diagnosed with preeclampsia or preeclampsia with severe features or superimposed preeclampsia with chronic hypertension - Candidates for expectant management and had no clinical indication for immediate delivery Exclusion Criteria: - Delivery within 48hr is highly likely - Maternal or fetal compromise that necessitated immediate delivery - Diabetes or gestational diabetes currently on metformin therapy - Reflux disease or other conditions currently on esomeprazole - Contraindications to metformin, esomeprazole - Baseline creatinine >124 µmol/L - Hypersensitivity to metformin or esomeprazole - Current use of metformin or esomeprazole - Metabolic acidosis - Use of drugs that might interact with metformin (glyburide, furosemide, or cationic drugs) - Multiple gestations |
Country | Name | City | State |
---|---|---|---|
United States | Christianacare Health System | Newark | Delaware |
Lead Sponsor | Collaborator |
---|---|
Christiana Care Health Services |
United States,
Cluver CA, Hiscock R, Decloedt EH, Hall DR, Schell S, Mol BW, Brownfoot F, Kaitu'u-Lino TJ, Walker SP, Tong S. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021 Sep 22;374:n2103. doi: 10.1136/bmj.n2103. — View Citation
Kaitu'u-Lino TJ, Brownfoot FC, Beard S, Cannon P, Hastie R, Nguyen TV, Binder NK, Tong S, Hannan NJ. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. PLoS One. 2018 Feb 21;13(2):e0188845. doi: 10.1371/journal.pone.0188845. eCollection 2018. — View Citation
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. Erratum In: N Engl J Med. 2008 Jul 3;359(1):106. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean plasma difference in sFlt-1 | sFlt-1 from serum samples | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months | |
Secondary | Mean plasma difference in vascular endothelial growth factor (VEGF) | VEGF from serum samples | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months | |
Secondary | Mean plasma difference in placental growth factor (PIGF) | PIGF from serum samples | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months | |
Secondary | Mean plasma difference in soluble endoglin (sEng) | sENG from serum samples | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months | |
Secondary | sFlt-1:PIGF ratio | sFLT-1:PIGF from serum samples | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months | |
Secondary | Prolongation of gestation | Difference in time of expectant management between experimental and control group. | Over the first 14 days after randomization and during the remainder of pregnancy, an average of 3-4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |